Acquiring Company
IASO Biotherapeutics
Acquired Company
MediSix Therapeutics
BostonManufacturingBiotechnologyHealth CareTherapeuticsBiotechnologyDescription
IASO Biotechnology announced the completion of its acquisition of MediSix Therapeutics, enhancing its cell therapy capabilities. This merger will leverage MediSix's PEBL technology while strengthening IASO Bio's R&D and commercial operations. The deal aims to accelerate innovative product development for global markets. Key leaders from both companies expressed optimism about the synergies created by this acquisition.
Don't miss IASO Biotherapeutics's next move
Get an email the moment IASO Biotherapeutics makes an acquisition, hires an exec, or expands — usually minutes after it happens.
One email per event. Unsubscribe anytime.
M&A Insights
Based on deal dataFrequently asked
Who acquired MediSix Therapeutics?
MediSix Therapeutics was acquired by IASO Biotherapeutics. The deal was reported on August 13, 2026. IASO Biotherapeutics, also known as IASO Bio, is a biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative cell therapy and antibody products. IASO Biotherapeutics is privately held and operates in Manufacturing.
When did IASO Biotherapeutics acquire MediSix Therapeutics?
IASO Biotherapeutics's acquisition of MediSix Therapeutics was reported on August 13, 2026. IASO Biotechnology announced the completion of its acquisition of MediSix Therapeutics, enhancing its cell therapy capabilities. This merger will leverage MediSix's PEBL technology while strengthening IASO Bio's R&D and commercial operations. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does MediSix Therapeutics do?
We are a Singapore-based immune engineering company developing novel cellular therapies to address T cell malignancies. It is privately held, operating in Biotechnology, and is based in Boston.